[PtCl(bbp)]Cl | 1309878-04-3

• 英文名称: [PtCl(bbp)]Cl
• 英文别名: [PtCl(2,6-bis(2-benzimidazolyl)pyridine)]Cl
• CAS: 1309878-04-3
• 化学式: C₁₉H₁₃ClN₅Pt*Cl
• 分子量: 577.332
• InChiKey: IAYJWBVDCHJLOC-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为产物：
  描述：

  2,6-双(2-苯并咪唑基)吡啶 、 potassium tetrachloroplatinate(II) 在 NaOH 作用下， 以 乙醇 、 水 为溶剂， 以70%的产率得到[PtCl(bbp)]Cl
  参考文献：
  名称：

  Synthesis, structural characterisation and biological studies of new mononuclear platinum(II) complexes with sterically hindered heterocyclic ligands

  摘要：

  Three novel cisplatin analogues were synthesized, designed according to an approach which violates the "classical'' structure-activity relationship, by replacing the diamine ligands with a planar N donor heterocycle giving a sterically hindered complex. Moreover, the sterical hindrance of antitumor drug candidates potentially makes them less susceptible to deactivation by sulphur-containing proteins and helping to overcome resistance mechanisms. The resulting mononuclear complexes of sterically hindered polidentate heterocyclic N ligands [PtCl(bbp)]Cl (1) [bbp = 2,6-bis(2-benzimidazolyl)pyridine], [PtCl2(dptdn)](H2O) (2) [dptdn = sodium 5,6-diphenyl-3-(2'-pyridyl)-1,2,4-triazine-4 '',4"'-disulfonate] and [(dptdn)(dpt)Pt]Cl-2(H2O) (3) [dpt = 5,6-diphenyl-3-(2'-pyridyl)-1,2,4-triazine] have been prepared and structurally characterised. Both neutral and ionic complexes are present, with monofunctional (1) and bifunctional Pt(II) moieties (2) and coordinatively saturated Pt(II) ions in the mixed ligand complex (3), whose size and shape enable them to behave as novel scaffolds for DNA binding. All complexes were tested "in vitro'' for their biological activity on human HT29 colorectal carcinoma and HepG2 hepatoma cells. The complexes (1) and (3), endowed with a positive charge, showed a potent cytotoxic activity and reduced cell viability with an efficacy higher than that of cisplatin; whilst the neutral bifunctional compound (2) was inactive. IC50 values have been calculated for the active compounds. The cytotoxic effects were confirmed by the accumulation of treated cells in subG0/G1 phase of cell cycle, by the loss of mitochondrial potential (Delta psi(m)) and by the chromatin condensation or fragmentation observed by means of fluorescence microscopy after Hoechst 33258 nuclear staining. A study on intracellular platinum uptake in HT29 cell line has been also performed and data obtained strongly suggest that the cytotoxicity of new tested complexes reported in this work is based on a different pharmacodynamic pattern with respect to cisplatin. (C) 2011 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2011.01.047